Get the latest tech news
Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs
Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and weight-loss drugs, Mounjaro and Zepbound.
“There are some ways that compounders tailor a medication to the patient, such as by adding another ingredient that might help with a side effect or an additional concern or diagnosis,” says Annie Lambert, a pharmacist and clinical program manager at information services firm Wolters Kluwer. In its suit against Mochi, Eli Lilly claims the telehealth company “switched dosages and prescriptions for patients en masse at least five times—with corporate interests, rather than doctor decisionmaking—driving the changes.” Those changes, Lilly alleges, included creating two new formulas containing a niacinamide additive and pyridoxine, both forms of vitamin B that the pharma company argues have not been proven to be safe or effective when combined with tirzepatide.
Or read this on Wired